Trial Profile

An Open-label, Single-arm, Pilot Study to Evaluate the Effect of XmAb5871 on Disease Activity in Patients With IgG4-Related Disease.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obexelimab (Primary)
Indications Immunoglobulin G4-related disease
Focus Therapeutic Use
Sponsors Xencor

Most Recent Events

15 Nov 2023 Results of a PopPK model analysis from four clinical trials: a first-in-human, single-ascending dose study in healthy volunteers; 2) a multiple-ascending dose study in patients with RA; 3) an open-label study in patients with IgG4-RD; and 4) a PK and relative bioavailability study.
01 Aug 2023 Results presented in the Zenas Biopharma Media Release.
01 Aug 2023 According to a Zenas Biopharma media release, results from this trial were published in the Lancet Rheumatology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com